Term Sheet

The latest on private equity, M&A, deals and movements — from Wall Street to Silicon Valley

Exclusive: Atlas Venture raises ninth fund

May 1, 2013: 10:28 AM ET

atlas-venture-logoBoston-area VC firm rebounds with new fund.

FORTUNE -- The first time I ever spoke with venture capitalist Jeff Fagnan was January 2009. I had heard that his firm, Atlas Venture, was cutting back on staff after finishing up fundraising more than $100 million below its $400 million target (and an even farther cry from the $750 million it had raised in the dotcom heyday). Not too enjoyable of a conversation. Neither was a follow-up about how Atlas basically would begin to wind down its London office, which meant additional layoffs.

At the time, Fagnan sounded hopeful that Atlas could turn things around by slimming down and refocusing. I was highly skeptical because, well, few VC firms survive a steep fall from grace. Remember, Atlas once had more than a dozen partners and offices all over Europe and North America. Now it was just a small handful of folks in Boston – with a lot less cash and very questionable future prospects.

But it seems I was wrong. The firm has just closed on its ninth fund with $265 million in capital commitments, which is $15 million above what it had been calling its hard cap. And there was plenty of over-subscription beyond that.

So Fagnan seemed to be in much better spirits yesterday when we had lunch to discuss the news. He explained that the big change was refocusing almost all of the firm's new deal activity around Boston (save for a few opportunistic Valley plays), with a focus on providing lots of seed capital (<$1m) before agreeing to lead Series A's.

"You can actually get lots of data now with relatively little money," Fagnan explains, adding that he views 'signaling risk' concerns as overblown. "Seeds also let us get checks to the entrepreneurs faster, and the entrepreneur knows we have pockets deep enough to do the Series A if things are progressing in the right direction."

He adds that this strategy is working not only for IT, but also for life sciences (where Atlas investments mostly in biotherapeutics – often partnering early with big pharma on development/option deals).

"I think they're going to dominate the Boston seed market, maybe alongside Google Ventures, because they spend their time in Boston instead of in New York" says an Atlas limited partner. "I cannot think of another firm that's gone through such a transformation and came out on the other side."

Sign up for Dan's daily email newsletter on deals and deal-makers: GetTermSheet.com

Join the Conversation
About This Author
Dan Primack
Dan Primack
Senior Editor, Fortune

Dan Primack joined Fortune.com in September 2010 to cover deals and dealmakers, from Wall Street to Sand Hill Road. Previously, Dan was an editor-at-large with Thomson Reuters, where he launched both peHUB.com and the peHUB Wire email service. In a past journalistic life, Dan ran a community paper in Roxbury, Massachusetts. He currently lives just outside of Boston.

Email a Tip | @danprimack | RSS
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Powered by WordPress.com VIP.